Danesi R - Search Results

1

Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.

Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, Sparreboom A, Dahut WL, Figg WD. Hamada A, et al. Among authors: danesi r. Urology. 2007 Aug;70(2):217-20. doi: 10.1016/j.urology.2007.06.1097. Urology. 2007. PMID: 17826473 Free PMC article.

2

Effect of suramin on human prostate cancer cells in vitro.

La Rocca RV, Danesi R, Cooper MR, Jamis-Dow CA, Ewing MW, Linehan WM, Myers CE. La Rocca RV, et al. Among authors: danesi r. J Urol. 1991 Feb;145(2):393-8. doi: 10.1016/s0022-5347(17)38351-9. J Urol. 1991. PMID: 1824865

3

Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells.

Danesi R, Figg WD, Reed E, Myers CE. Danesi R, et al. Mol Pharmacol. 1995 Jun;47(6):1106-11. Mol Pharmacol. 1995. PMID: 7603448

4

Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.

Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Sparreboom A, et al. Among authors: danesi r. Drug Resist Updat. 2003 Apr;6(2):71-84. doi: 10.1016/s1368-7646(03)00005-0. Drug Resist Updat. 2003. PMID: 12729805 Review.

5

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, Sparreboom A. Paoluzzi L, et al. Among authors: danesi r. J Clin Pharmacol. 2004 Aug;44(8):854-60. doi: 10.1177/0091270004267159. J Clin Pharmacol. 2004. PMID: 15286088

6

CYP2D6 polymorphisms and the impact on tamoxifen therapy.

Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. Beverage JN, et al. Among authors: danesi r. J Pharm Sci. 2007 Sep;96(9):2224-31. doi: 10.1002/jps.20892. J Pharm Sci. 2007. PMID: 17518364 Review.

7

Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.

Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A. Sissung TM, et al. Among authors: danesi r. Mol Cancer Ther. 2008 Jan;7(1):19-26. doi: 10.1158/1535-7163.MCT-07-0557. Epub 2008 Jan 9. Mol Cancer Ther. 2008. PMID: 18187806

8

Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.

Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD. Hamada A, et al. Among authors: danesi r. Clin Cancer Res. 2008 Jun 1;14(11):3312-8. doi: 10.1158/1078-0432.CCR-07-4118. Clin Cancer Res. 2008. PMID: 18519758 Free PMC article.

9

A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.

Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD. Sharifi N, et al. Among authors: danesi r. BJU Int. 2008 Aug 5;102(5):617-21. doi: 10.1111/j.1464-410X.2008.07629.x. Epub 2008 Jun 4. BJU Int. 2008. PMID: 18537956 Free PMC article.

10

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.

Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD. Jain L, et al. Among authors: danesi r. Mol Cancer Ther. 2009 Sep;8(9):2496-508. doi: 10.1158/1535-7163.MCT-09-0302. Epub 2009 Sep 15. Mol Cancer Ther. 2009. PMID: 19755511 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

518 results

Search Page